Tuesday Briefing: Your Need-to-Know Information for May 17

May 17, 2016


First a $1 billion investment and then an IPO, Didi Chuxing has what it takes to get the financial crowd have it on their radar and dominate the top of Sentifi Top Attentions list.

didi1. Didi Chuxing: Planned IPO still gets the crowd talking [944% increase in voices in the last 24h]

Photo by Zhang Peng/LightRocket via Getty Images

Even though it’s already been a day after Didi Chuxing announced an planned IPO in New York, the crowd is still talking about it. The company still hasn’t offered any detail about it, but one thing’s for sure that if the IPO happens, it will be the biggest IPO by a Chinese company since Alibaba’s record 2014 IPO.




2. Total SA: Opens a $5 billion gas plant [887% increase in voices in the last 24h]

The French energy company opens a $5 billion gas processing plant on the British Shetland Islands. The plant is expected to produce enough energy for 2 million homes.

3. SandRidge Energy: Files for Chapter 11 bankruptcy [819% increase in voices in the last 24h]

The energy company plans to convert $3.7 billion of long-term debt into equity as it files for Chapter 11 bankruptcy and seeks protection from a bankruptcy court. It has requested the court to allow it to continue day-to-day operations where it continues to pay wages, royalties and interest without interruption. Many analysts on Wall Street hold a firm belief SandRidge won’t be the last energy to file for bankruptcy.

4. Anacor Pharma: Pfizer sets sight on Anacor for acquisition [723% increase in voices in the last 24h]

Image by bidnessetc

Anacor sees its shares go up 57% after it agrees to a $5.2 billion offer from Pfizer. This acquisition represents a shift in Pfizer’s strategy, from chasing large-scale mergers to strengthening its drug portfolio. This news also came as a surprise as analysts expected Allergan to acquire Anacor instead. With Anacor joining the rank, Pfizer now has access to crisaborole, a non-steroidal topical gel, which it believes to reach peak sales of $2 billion.


5. Bank of Baroda: Shares slump on quarterly loss [656% increase in voices in the last 24h]

Shares of the bank plummet more than 10% as it reports a new loss for the March 2016 quarter, a sharp contrast from the net profit in the same quarter last year. The disappointing number is the direct result of a 227% increase in provisioning for bad loans.

6. Alibaba Pictures: Successful funding round is still being discussed [528% increase in voices in the last 24h]

Alibaba Pictures had a very successful funding round for its online movie ticketing platform yesterday with $260 million. The leading investors were CDH investments, Ant Financial Services and Sina Corp. Alibaba Pictures aims to strengthen its position and market share with this Series A funding.

7. Aduro Biotech: Faces an investigation into fraud and liability [522% increase in voices in the last 24h]

Pomerantz Firm is launching an investigation into the claims of Aduro’s investors that the company has violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. Those two sections relate to fraud and liability. Following the news, Aduro’s shares fall 32%.

8. ICAP: Plans a name change on top of disappointing earnings [473% increase in voices in the last 24h]

The U.K.-based financial services firm reports drops in revenue, trading operating profit, trading profit before tax and profit before tax for the year ended March 2016 compare to the previous year. Macro economic environment, historically low and negative interest rates, and continue bank deleveraging are the reason the firm cites to explain for the disappointing results. The firm also makes an announcement of a potential name change to NEX Group following the sale of its global hybrid voice broking and information business.

9. Shanghai Fosun Pharma: Makes a non-bidding offer for India-based Gland Pharma [400% increase in voices in the last 24h]


The Chinese company plans to acquire 96% of Gland Pharma from existing shareholders to strengthen its drug manufacturing, research and development capacity. Gland Pharma is also getting offers ranging from $1.1 billion to $1.2 billion from Advent International and Baxter International.




10. Piramal Enterprises Ltd: Chairman hints on restructuring [379% increase in voices in the last 24h]

An impending restructuring might be waiting for the company, if what the chairman said is accurate. To be more specific, the company plans to restructure and demerge healthcare and financial services businesses

If you want to harness the wisdom and insights from the crowd to monitor your portfolio free of charge, please sign up for myMarkets.